Opioid Withdrawal Treatment Market Size

Opioid Withdrawal Treatment Market Overview

The opioid withdrawal treatment market is expected to reach USD 3.23 billion by 2032 at 10.3% CAGR during the forecast period 2023-2032. Opioid Withdrawal creates problems when a person feels sudden vomiting and nausea from the extended use of opioids. The reaction will raise drug cravings, anxiety and restless legs, increasing heartbeat rate and also sweating.

This sudden illness occurs due to misuse of the type of opioid medicines, wrong treatment and even drug addiction. Opioid medicines are naturally used in chronic and repulsing illnesses. It increases the rate of morbidity and mortality. This medicine targets to reduce relapse. The patients with OUD signify abstain. Thabstaincribed medication of opioids and diverted opioid medicines are the main reasons for this. In some reports, it suggests addiction and life-threatening conditions.

As per the data of the centres for disease Control and Prevention, the death case was 33000 people due to misuse of this drug in 2015. The increasing rate of an overdose of this drug is increasing. As the reports suggest this is one of the highest and most effective drugs for pain. The use of these drugs is further used in cancer pain cures and many others. Furthermore, the increasing facts of this drug use are showing grave concern globally.

Opioid Withdrawal Treatment Market COVID-19 analysis

The deadly virus of COVID-19 has greatly affected many businesses globally. Even the pandemic caused an isolation period for affected people. Most of the physicians were fear of suggesting this drug due to the effects of pain in the COVID-19 situation. The pandemic also slowed down the treatment of chronic pain in patients. The delayed treatment of many patients leads to the overuse of this drug. This caused a great effect of nauseous feeling and more anxiety among patients. Furthermore, the ongoing situation of osteoarthritis and the old ageing become the main reason for the withdrawal of this drug.

COVID-19 created a major health crisis among people. During this pandemic period, the situation rose high. The economic conditions worldwide are devastated. This market has risen to 10% around this time. The opioid withdrawal treatment market growth mainly focused those chronic pain patients and senior citizens. In the United States, and European Union this market had seen a great growth further. Even in the painful diabetic neuropathy market, this medicine withdrawal also was in high demand. Moreover, the market of opioid withdrawal treatment saw good profit during the pandemic period due to a decrease in pain among patients. In 2018, the United States foods and Drug Administration launched a policy. The main strategy of this policy was a reduction in the misuse of opioids. It also caused a high chance of another disease among patients. There is no particular mention of the taken steps of the government.

Market dynamics

The main market dynamics of the market of opioid withdrawal treatment are hidden in the main three factors market drivers, opportunities, restraints, challenges and cumulative growth analysis.

Market drivers

The main market driver of the opioid withdrawal treatment market is the high demand for pain relief. In the fact, the opioid is highly effective in pain relief. It also has great effects on analgesia. This medicine is also effective in chronic pain and osteoarthritis. This driver highlights the market demand among people. Another market driving strategy in this segment is lower back pain, cancer, and post-surgical pain. This medicine also has great demand in the diabetic neuropathy market. This medicine is also used in pain management programs. These market drivers are the main reason for the market growth of the opioid withdrawal treatment.

Market Opportunities

The market has a great opportunity for further growth in upcoming years. As per the discussed facts, the United Kingdom and the United States face a steady growth of the increasing disease of osteoarthritis. This factor is the main lead to steady growth. Even the reports of the international journal of immunopathology and pharmacology suggest that the common rate of neuropathic pain among the population was calculated. The rate was around 3% to 17% in 2019. Thus the main reason for the growth of the market. These reasons create great opportunities for the demand for this medicine in the United States and the United Kingdom.

Market Restraints

Although this medicine is greatly effective in pain. It causes many other diseases among patients. Sometimes the overdose of this medicine can lead to life risk situation. This medicine also creates addiction. It has some properties of effective drugs which can lead up to heart disease.

Opioid Withdrawal Treatment Market Challenges

The opioid withdrawal treatment market has also some challenges. The doctors are avoiding this medicine due to its life taking risks. The governments are taking a step forward to misuse these drugs. The stores are strictly prohibiting the sales of these drugs alternative medications with low dangerous properties are taking place. The several policies are making challenges for this market.

Opioid Withdrawal Treatment Market segmentation

The market segmentation of the opioid withdrawal treatment market is divided into a few segment categories. The segments are 1. By type, 2. By use, 3. The regional division and also 4. distribution channels.

By type

The opioid drug modules have certain types of variations. The major popular opioid medication on the market is Buprenorphine. This drug module form is rapidly used in many diseases to get pain relief. The next popular forms of this medicine are Methadone, Naltrexone and others.

By use

As the medicine has the properties of pain relief, it has great use in pain management therapies. The medicine also use in osteoarthritis and major pain among patients. This medicine also has popularity among old age citizens.

By regional division

The use of this medicine is also very popular in the United States, the United Kingdom, the Asia Pacific region, and also the Middle East region. The market has spreaded in different countries.

The distribution channels

The distribution channels of this market is spread between retail medical shops, hospital Medical store and the online medical stores.

Opioid Withdrawal Treatment Market Regional division

The major regional division of this market has between four major regions. The North America, the aisa Pacific region, the European countries and the middle East portion. Furthermore, the North America also includes Canada, latin America, Brazil, Argentina. The major shareholder of the opioid withdrawal treatment market is north America. The growing patients with disease like chronic pain, lower back pain, arthritis are the main the reason of the growth of this market region. Data further suggest the growing number of old age person with pain problem in United States are also the main reason of the market growth in this region.

The second largest market shareholders of this market is Europe union. Germany, france, Italy and many other countries in European region are also showing great interest in this market region.The Asia Pacific and the middle East portion of this market are growing. Furthermore, the reports also suggests the aisa Pacific region market also has potential status of growth of this market segment in upcoming years. The developong countries like india, Japan, china are showing great interest in this market region. In middle East portion the United Arabia Emirates are showing interest in this market growth.

Opioid Withdrawal Treatment Market Competitive landscape

The competitive landscape reports also suggest the growing market players in this opioid withdrawal treatment.

• Orexo AB


• Biodelivery sciences International Inc.


• Viatris Inc.


• Titan pharmaceuticals Inc.


• Mallinckrodt pharmaceuticals


• Alkermes


• Teva pharmaceuticals industries Ltd.

Opioid Withdrawal Treatment Market Recent developments

November 2023Akili Interactive announces that its investigational digital therapeutic, Akili Interactive Labs’ AKL-T01, has been granted FDA Breakthrough Therapy Designation for the treatment of opioid withdrawal syndrome. Akili Interactive Labs’ AKL-T01 is a non-invasive, prescription-use digital therapeutic that uses a video game-like interface to help patients manage the symptoms of opioid withdrawal.Sublocade Pharma announces that its investigational drug, Sublocade® (buprenorphine extended-release subcutaneous injection), has been granted FDA Priority Review for the treatment of opioid use disorder (OUD). Sublocade® is a once-monthly injectable form of buprenorphine, a medication that is used to treat OUD.Vivitrol Pharmaceuticals announces that its drug, Vivitrol® (naltrexone extended-release injectable suspension), has been granted FDA approval for the prevention of relapse to opioid addiction in adults who have been abstinent from opioids for at least 7 days. Vivitrol® is a once-monthly injectable form of naltrexone, a medication that blocks the effects of opioids.October 2023Pear Therapeutics' reSET® digital therapeutic receives FDA approval for the treatment of substance use disorder (SUD) in adults, including opioid use disorder (OUD). reSET® is a prescription-use digital therapeutic that uses a combination of cognitive-behavioral therapy (CBT) and mindfulness techniques to help patients manage the symptoms of SUD.Ethypharm announces that it has received FDA approval for its drug, Brixham Pharmaceuticals' Bunavail® (buprenorphine/naloxone sublingual tablet), for the treatment of moderate to severe opioid use disorder (OUD) in adults. Brixham Pharmaceuticals' Bunavail® is a combination tablet of buprenorphine and naloxone, which is designed to reduce the risk of overdose.September 2023The National Institute on Drug Abuse (NIDA) announces that it has awarded a $30 million grant to a consortium of researchers to develop new and innovative treatments for opioid withdrawal syndrome. The grant will fund research into a variety of new approaches to opioid withdrawal treatment, including medication-assisted treatment (MAT), behavioral therapy, and complementary and alternative medicine (CAM).